Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
3.17
Nov 19 • 2:32 PM ET Dollar change-0.26 Percentage change(-7.58%)
Index
-
Market Cap
6.77M
Enterprise Value
-3.25M
Income
-40.44M
Sales
0.00M
Book/sh
3.79
Cash/sh
4.69
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
1
IPO
Mar 17, 1980
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.84
P/C
0.68
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
3.66
Current Ratio
3.66
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-118.04
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
31.76% 49.68%
Sales past 3/5Y
- -
EPS Y/Y TTM
60.31%
Sales Y/Y TTM
-
EPS Q/Q
-107.60%
Sales Q/Q
-
Insider Own
16.00%
Insider Trans
0.00%
Inst Own
4.11%
Inst Trans
3.46%
ROA
-455.54%
ROE
-627.84%
ROIC
-434.61%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-29.43%
SMA50
-47.06%
SMA200
-64.21%
Trades
Shs Outstand
2.06M
Shs Float
1.80M
52W High
23.60 -86.57%
52W Low
3.10 2.26%
Volatility
14.91% 10.90%
ATR (14)
0.54
RSI (14)
28.57
Beta
0.92
Rel Volume
0.88
Avg Volume
76.06K
Volume
52,705
Perf Week
-17.45%
Perf Month
-41.40%
Perf Quarter
-56.06%
Perf Half Y
-70.72%
Perf YTD
-83.85%
Perf Year
-81.35%
Perf 3Y
-98.21%
Perf 5Y
-99.92%
Perf 10Y
-100.00%
Prev Close
3.43
Price
3.17
Change %
-7.58%
Consensus
Strong Buy
Avg. Price Target
$75.00
Implied Upside
+2,265.9%
Analysts4incl. previous ratings
Rating Distribution4 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Dec 02, 2024Initiated
RROTH MKM
Buy$11+247.0%
May 24, 2021Initiated
HH.C. Wainwright
Buy$25+688.6%
Apr 13, 2021Initiated
RILY logoRB. Riley Securities
Buy$21+562.5%
Mar 17, 2021Initiated
RROTH Capital
Buy$25+688.6%
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary TriKE and Dual Targeting TriKE platforms. Its product candidates include GTB-3650, a CD33-targeted therapy for relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, and GTB-5550, a B7-H3-targeted therapy for solid tumors. The company was founded in 1965 and is headquartered in San Francisco, CA.
PresidentMr. Michael Martin Breen L.L.B.
CFO & SecretaryMr. Alan Louis Urban CPA